Whitepaper: Manufacturing Drug Delivery Systems | Making Inhaled Therapies Fit for the Future | Improving the Sustainability of Pressurised Metered Dose Inhalers

Since their introduction in 1956, pressurised metered dose inhalers (pMDIs) have become the dominant treatment choice for patients suffering from common respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). However, unbeknown to most patients and many doctors, pMDIs account for 3.9% of NHS’s annual carbon emissions. Here we will discuss how formulation changes might be the answer to the pMDI-related sustainability problem.